Brodalumab  (Synonyms: AMG 827; KHK4827)

Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis^[1][2].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

IL-17R^[1]

Brodalumab (AMG 827) blocks the biological activity of IL-17A, IL-17F and IL17-A/F heterodimer signaling through the IL-17RA/RC complex, as well as IL-25 (IL-17E) signaling through the IL-17RA/RB complex^[2].
Brodalumab is capable of inhibiting the inflammatory process in psoriasis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.06 kDa

1174395-19-7

Liquid

Colorless to light yellow

[Brodalumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Immobilized IL-17RA Protein, Human can bind Brodalumab. The EC₅₀ for this effect is 7.1 ng/mL.

• [1]. Papp KA, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 Mar 29;366(13):1181-9.  [Content Brief]

  [2]. Martin DA, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther. 2013 Oct 25;15(5):R164.  [Content Brief]